Agilent Announces Launch of Global Biomarker Pathologist Training Program
Agilent Technologies Inc. (NYSE: A) has launched the Biomarker Pathologist Training Program, aimed at enhancing the ability of pathologists to accurately score biomarkers. This global initiative, initially available in Europe and North America, leverages Agilent's expertise in companion diagnostics and partnerships with pharmaceutical firms. The program includes both basic and advanced training, offered digitally via Pathcore Scholar. It is designed to improve patient outcomes by ensuring high concordance in biomarker scoring, critical for the increasing prevalence of targeted therapies in oncology.
- Launch of the Biomarker Pathologist Training Program, enhancing pathologists' skills.
- Focuses on accurate biomarker scoring, which is crucial for targeted therapies.
- Utilizes Agilent's expertise and partnerships with pharmaceutical companies.
- Training available across different levels and formats to cater to individual needs.
- None.
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of the Biomarker Pathologist Training Program, a global initiative created to empower pathologists to score biomarkers accurately and confidently. Developed by Agilent – a worldwide leader in developing and commercializing diagnostic products – this training program incorporates Agilent’s unique expertise in companion diagnostics and partnership with top pharmaceutical companies.
Biomarker testing has profoundly influenced the practice of both pathology and oncology today. Targeted therapies have seen more than
"We are excited to successfully launch the Agilent Biomarker Pathologist Training Program to further support our efforts in the fight against cancer," said Simon Oestergaard, general manager and vice president of Pathology at Agilent. "This program will allow pathologists to learn and practice scoring techniques, to gain the necessary confidence and competence to accurately score biomarker cases in their own laboratories. Combined with Agilent’s high-quality pathology staining solutions this training program will help ensure pathologists can score cases with high concordance."
The program, which will initially be available in Europe and North America, followed by China and Asia, utilizes a digital platform, Pathcore Scholar, where attendees can navigate both standard and challenging cases. For Agilent products with approved indications, the training, supports Agilent biomarkers only and will provide strategies and best practices for delivering optimal scoring results, which will in turn improve patient outcomes. Training will be offered at different levels, from basic to advanced, and both in-person and remotely, to address individual training requirements.
For more information visit: https://explore.agilent.com/biomarker-training-program
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics and applied chemical markets delivering insight and innovation toward improving the quality of life. Agilent instruments, software, services, solutions and people provide trusted answers to customers' most challenging questions. The company generated revenue of
References:
-
Targeted Cancer Therapies
https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies/targeted-therapies-fact-sheet (accessed May 11, 2020) - Badve, S.; Kumar, G. L., Eds. Predictive Biomarkers in Oncology; Applications in Precision Medicine; Springer: Cham, Switzerland, 2019
